BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders... Show more
Expect a price pull-back in the near future.
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BRSYF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.046) is normal, around the industry mean (59.733). P/E Ratio (39.214) is within average values for comparable stocks, (38.608). BRSYF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.698). BRSYF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.020). P/S Ratio (4.690) is also within normal values, averaging (92.794).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry MedicalNursingServices
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RRGIX | 7.16 | N/A | N/A |
DWS RREEF Global Real Estate Secc Inst | |||
FDEIX | 28.22 | N/A | N/A |
Fidelity Advisor Capital Development I | |||
GSMYX | 23.80 | N/A | N/A |
Goldman Sachs Small/Mid Cap Growth Instl | |||
AIVOX | 11.01 | N/A | N/A |
American Century International Opps A | |||
TISLX | 12.06 | N/A | N/A |
Transamerica Intl Sust Eq R6 |
A.I.dvisor indicates that over the last year, BRSYF has been loosely correlated with ANSLY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if BRSYF jumps, then ANSLY could also see price increases.
Ticker / NAME | Correlation To BRSYF | 1D Price Change % | ||
---|---|---|---|---|
BRSYF | 100% | N/A | ||
ANSLY - BRSYF | 61% Loosely correlated | N/A | ||
IOBCF - BRSYF | 39% Loosely correlated | N/A | ||
VERO - BRSYF | 30% Poorly correlated | +0.41% | ||
WUXIF - BRSYF | 27% Poorly correlated | +84.43% | ||
SNWV - BRSYF | 25% Poorly correlated | -5.27% | ||
More |
Ticker / NAME | Correlation To BRSYF | 1D Price Change % |
---|---|---|
BRSYF | 100% | N/A |
Health Services category (440 stocks) | 5% Poorly correlated | +3.43% |
Medical/Nursing Services category (226 stocks) | 4% Poorly correlated | +6.56% |